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ABSTRACT 
Belatacept is a novel immunosuppressive agent that may be used as an alternative to 
calcineurin inhibitors (CNI) in immunosuppression (IS) regimens. We report two cases of 
pancreas transplant that were switched from tacrolimus (TAC) to belatacept. Case 1: 38‐
year‐old female with pancreas transplant alone maintained on TAC‐based IS regimen 
whose serum creatinine (SCr) slowly deteriorated from 0.6 mg/dL at baseline to 
2.2 mg/dL, 16 months posttransplant. A native kidney biopsy performed showed CNI 
toxicity. The patient was started on belatacept and TAC was eliminated. Case 2: 49‐year‐
old female with simultaneous pancreas–kidney transplant, maintained on TAC‐based 
regimen where the SCr worsened over an initial 3‐month period from a baseline of 1.0 to 
3.0 mg/dL. Belatacept was started and TAC was lowered. Due to persistent graft 
dysfunction and kidney transplant biopsy still showing changes consistent with CNI 
toxicity, the TAC was then discontinued. At >1 year postbelatacept and off TAC follow‐
up, kidney function as measured by SCr remains stable at 1.0 ± 0.2 mg/dL in both 
recipients. Neither patient developed rejection following the switch, and pancreas allograft 
function remains stable in both recipients. 
ABBREVIATIONS 
CAN: chronic allograft nephropathy 
CKD: chronic kidney disease 
CNI: calcineurin inhibitors ____________________________________________________
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DM: diabetes mellitus 
DSA: donor‐specific antibody 
EBV: Epstein–Barr virus 
FBG: fasting blood glucose 
GFR: glomerular filtration rate 
IS: immunosuppression 
MMF: mycophenolate mofetil 
PAS: periodic acid‐Schiff 
PRA: panel reactive antibodies 
PTA: pancreas transplantation alone 
SCr: serum creatinine 
SPK: simultaneous pancreas–kidney transplant 
SRL: sirolimus 
TAC: tacrolimus 
UPr/UCr: random urine protein to urine creatinine ratio 
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INTRODUCTION 
The calcineurin inhibitors (CNI), cyclosporine and tacrolimus (TAC), continue to be the 
primary agents used as a part of immunosuppression (IS) regimens for nearly all types of 
solid organ transplantations 1-3. Low rejection rates, as well as excellent graft and patient 
survival rates have been observed following the introduction of these agents. However, 
one of the drawbacks to CNI therapy is their propensity to cause chronic nephrotoxicity 
leading to interstitial fibrosis and tubular atrophy. There are many potential mechanisms 
aside from vasoconstriction, and pathologic changes from CNI in the transplanted kidney 
are observed as early as 1 year. These changes increase remarkably in the years 
following transplantation and contribute to fibrosis, atrophy and transplant glomerulopathy 
eventually leading to graft loss 4, 5. 
Unlike the kidney, the pancreas is highly immunogenic and associated with a high risk of 
rejection especially among nonuremic recipients of pancreas transplantation alone 
(PTA) 6. This has led to the use of regimens with higher concentrations of CNI 3, 7. 
Belatacept, the first selective T cell costimulation blocker approved to prevent acute 
rejection in adult renal transplant recipients does not cause nephrotoxicity. Recent studies 
comparing regimens in which belatacept was used to either replace or reduce the dose 
of the CNI have shown success in low risk kidney transplant recipients 8, 9. Furthermore, 
switching patients maintained on a CNI‐based regimen to a belatacept‐based regimen 
was shown to be effective in preventing the progression of kidney allograft dysfunction 
from CNI toxicity 10. 
There have been no published reports describing the use of belatacept to prevent the 
progression of chronic kidney disease (CKD) in pancreas transplant recipients or its use 
as a primary IS regimen in pancreas transplantation. In this report, we describe our 
experience of converting TAC to belatacept in two pancreas transplant recipients to 
preserve renal function. 
CASE PRESENTATION 
Case 1: pancreas transplant alone 
 
 
A 38‐year‐old female with a history of chronic pancreatitis and type 1 diabetes mellitus 
(DM) following a total pancreatectomy underwent a PTA for recurrent hypoglycemic 
unawareness episodes. At the time of transplant, the patient had normal kidney function 
(serum creatinine [SCr] 0.8 mg/dL, undetectable proteinuria). The patient's pretransplant 
Flow panel reactive antibodies (PRA) Class I and Class II were 0. Induction therapy 
consisted of five doses of antithymocyte globulin (1 mg/kg/dose) and a single dose of 
rituximab (150 mg/m2). Maintenance IS regimen consisted of a triple drug IS regimen of 
TAC (target trough level, 8–10 ng/mL), sirolimus (SRL) (target trough level, 3–5 ng/mL) 
and mycophenolate mofetil (MMF) 500 mg orally twice daily. There were no other 
nephrotoxic medications and the patient received prophylaxis with valganciclovir and 
trimethoprim/sulfamethoxazole. 
Over a 16‐month period posttransplant, the patient had excellent pancreatic allograft 
function, with a fasting blood glucose (FBG) of 91 mg/dL, A1C 5.6% and serum lipase 
20 U/L. A gradual decline in renal function occurred over 6 months with SCr increasing 
from 0.6 mg/dL at baseline to 2.2 mg/dL. Prerenal causes were excluded and BK virus 
screening was negative. The mean TAC trough levels at 1, 3, 6, 12, 18 and 22 months 
were: 7.5, 8.3, 7.9, 8.1, 6.9 and 6.0 ng/mL, respectively. The mean SRL trough levels 
were 4.0, 3.7, 4.1, 3.1, 3.8 and 4.2 ng/mL, respectively. A native kidney biopsy was 
performed showing 40 glomeruli being sampled with approximately 25% obsolescence. 
Overall glomerular size and cellularity were within normal limits. Mesangial matrix lacked 
diabetic type “KW nodules.” A few glomeruli (∼10–20%) showed mild mesangiolysis. 
Glomerular capillary loop basement membranes were focally wrinkled and thickened. 
Tubules showed moderate atrophy (∼50% of sampled tubules) with some lumina 
containing cell debris and Tamm–Horsfall protein casts. There was mild interstitial fibrosis 
and infiltrates of lymphocytes. Arteries show moderate fibrous intimal thickening without 
onion‐skin change. Arterioles showed severe subintimal hyalinosis (Figure 1). 
 
 
 
Figure 1: Light microscopic findings of native kidney biopsy in patient with pancreas 
transplant alone. (A) Periodic acid‐Schiff (PAS) stain: arrows indicate hyaline 
arteriosclerosis in a background of moderate tubular atrophy. (B) Allochrome stain from 
the same field but deeper level of sectioning. Arrow indicates hyaline arteriosclerosis in a 
background of mild interstitial fibrosis. (C) PAS stain: striped pattern of fibrosis and tubular 
atrophy. (D) Allochrome stain: asterisks indicate glomerular obsolescence. 
After screening to ensure the patient was Epstein–Barr virus (EBV) IgG positive, 
belatacept therapy was initiated. Belatacept was administered as 5 mg/kg dose via 
intravenous infusion on days 1, 15, 29, 42, 57 and then every 28 days thereafter 10. The 
TAC dose was gradually reduced by 25% each week with complete stop at 4 weeks. No 
changes were made in SRL target levels and maintained between 3 and 5 ng/mL. 
Following conversion, there was a gradual improvement in SCr (Figure 2). Labs from the 
last follow‐up visit which was 17 months postconversion showed SCr of 1.0 mg/dL, 
random urine protein to urine creatinine ratio (UPr/UCr) 0.18, A1C 5.7%, FBG 98 mg/dL, 
serum lipase 23 U/L and C‐peptide 2.9 ng/mL. HLA donor‐specific antibody (DSA) and 
anti‐insulin autoantibodies were undetectable, and serum EBV and BK virus remain 
negative. 
 
 
 
Figure 2: Kidney and pancreas function over time. Dotted line indicates switch from 
tacrolimus to belatacept. Mean SCr, serum creatinine; UPr/UCr, random urine protein to 
urine creatinine ratio; BGL, blood glucose levels. Same symbols are used to depict the 
variables. 
Case 2: Simultaneous pancreas–kidney transplant 
A 49‐year‐old female with history of insulin dependent DM, undetectable fasting C‐peptide 
levels, hypoglycemic unawareness and end‐stage renal disease with a prior failed kidney 
transplant underwent a zero antigen mismatch simultaneous pancreas–kidney transplant 
(SPK). Her other co‐morbid conditions included, mild obesity, peripheral arterial disease, 
congestive heart failure, hypertension, hyperlipidemia, hypothyroidism, seizure disorder, 
mild mitral stenosis and mild pulmonary hypertension. The patient was highly sensitized 
with Class 1 and Class II Flow PRA of 84% and 56%, respectively, and had received 
desensitization therapy with intravenous immunoglobulin and rituximab while on the 
waiting list. Induction regimen consisted of five doses of antithymocyte globulin, rabbit 
(1 mg/kg/dose) and maintenance IS consisted of a combination of TAC (target 12 h trough 
 
 
level, 8–10 ng/mL) and MMF 1000 mg twice a day. There were no other pertinent 
nephrotoxic medications and the patient received standard prophylaxis with valganciclovir 
and trimethoprim/sulfamethoxazole. 
The patient's FBG after transplant was 98 mg/dL, A1C 5.6%, C‐peptide 1.7 ng/mL, serum 
lipase 19 U/L. Renal function at 2 weeks posttransplant was normal with SCr 1.0 mg/dL 
and UPr/UCr of 0.10. Over a period of the next 3 months, the SCr gradually increased to 
3 mg/dL. Due to worsening graft function and history of congestive heart failure, diuretics 
were used during this course. The mean TAC trough levels at 1, 2 and 3 months were 
7.5, 8.0 and 6.7 ng/mL, respectively. It was then decided to start her on belatacept and 
minimize her TAC levels to 2–5 ng/mL. However, graft function remained poor at SCr of 
2.6 mg/dL, despite mean TAC levels of 3.3 mg/dL. At 7 weeks into belatacept therapy, a 
biopsy was performed with 19 glomeruli sampled. It revealed mild tubular necrosis and 
mild to moderate tubular atrophy with interstitial fibrosis. Arteries showed intimal 
thickening and arterioles showed subintimal hyalinosis. Glomerular obsolescence was 
minimal (1/19). 
Based on the biopsy results it was then decided to totally eliminate TAC and remain on a 
regimen of belatacept, MMF and SRL. The TAC dose was gradually reduced by 25% 
each week with complete stop at 4 weeks. When TAC was discontinued, SRL was 
initiated (24 h trough level 3–5 ng/mL). The mean SRL trough levels at 1, 3, 6 and 12 
months were 4.1, 3.8, 4.3 and 4.4 ng/mL, respectively. Over the next few weeks and 
months, the graft function improved gradually (Figure 2). One measurement of 
ImmuKnow® (Viracor‐IBT Laboratories, Lee's Summit, MO) ATP value of 283 ng/mL 
(moderate immune response range 226–524) was obtained 6 weeks after starting 
belatacept. The most recent labs obtained 16 months postconversion were SCr 
1.0 mg/dL, UPr/UCr 0.09, fasting C‐peptide 1.1 ng/mL, FBG 85 mg/dL, serum lipase 
19 U/L and A1C 4.7% (Figure 2). DSA and anti‐insulin autoantibodies remain 
undetectable, and serum EBV and BK remain negative. 
DISCUSSION 
CNI nephrotoxicity can occur despite maintaining CNI trough serum concentrations within 
the therapeutic range. Nephrotoxicity due to CNI is a clinicopathological entity whose 
 
 
diagnosis is difficult to establish and sometime can only be confirmed through renal 
biopsy findings or elimination of CNI. The histological features indicative of acute CNI 
toxicity are necrosis and dropout of individual myocytes, the onset of replacement of these 
myocytes with hyaline insudates in afferent arterioles and isometric vacuolation, 
predominantly in the straight proximal tubules. In chronic toxicity, beaded medial 
hyalinization of afferent arterioles, striped interstitial fibrosis and tubular atrophy are 
observed 5. However, as CNI nephrotoxicity can overlap with other pathological findings 
such as acute tubular necrosis, and chronic rejection/chronic allograft nephropathy 
(CAN), the confirmatory diagnosis usually requires minimization or elimination strategies. 
In our cases, the main rationale to switch to belatacept and eliminate TAC was to provide 
adequate IS for the pancreas transplant while at the same time preserving renal function. 
Based on the clinical course and biopsy findings, both cases clearly show that the poor 
renal function was due to TAC therapy. Belatacept has been studied extensively recently 
in kidney transplant patients 8-12. Treatment with belatacept is associated with better 
renal function, less CAN and an improved cardiovascular risk factor profile compared with 
cyclosporine. The overall safety profile of belatacept was similar to cyclosporine in the de 
novo setting. However, it has been associated with more severe early acute rejection 
episodes and an increased risk for posttransplant lymphoproliferative disorder affecting 
the central nervous system, particularly in those that were EBV IgG seronegative at the 
initiation of belatacept therapy. 
Pancreas transplantation has been increasingly accepted as an intervention to manage 
labile DM during the last few decades. Survival rates of pancreatic grafts have improved 
over time 6, 13. This may be because of better surgical techniques, but also largely due 
to reduction in early acute rejection from newer IS regimens 6. Pathologic changes from 
diabetes are frequently seen in native kidneys of PTA. These morphologic lesions of the 
native kidney disease have also been reported to reverse after PTA 14. However, 
proteinuria and kidney function after PTA remain important risk factors. Preexisting kidney 
dysfunction (SCr > 1.5 mg/dL), young age at transplantation and high TAC trough 
concentrations have been identified as risk factors for a decline in kidney function and 
progression to end‐stage renal disease following pancreas transplantation 3, 15. An 
 
 
estimated GFR diminution ranging from 33% to 44% at 5 years has been reported 16. 
Also in SPK, patient survival is more dependent on renal than on pancreas allograft 
survival 17. Hence preserving long‐term renal function remains an ultimately very 
important goal in renal and nonrenal organ transplantation. Conversion to mammalian 
target of rapamycin inhibitors is attempted in many cases to preserve renal function in 
kidney transplantation or other nonpancreas organ transplantation 18. However, short of 
nonrandomized single study reports of CNI elimination, there is a no data to support safe 
CNI free IS in pancreas transplantation 19. 
Our cases do have certain limitations. There are no follow‐up biopsies to see if the CNI‐
induced changes reversed or stabilized as the patients have maintained excellent renal 
function. We also do not have any tests of T cell reactivity (ELISPOT, ImmuKnow®) 
serially performed on our cases to further study the immune response in this approach in 
pancreas recipients. We did not have any formal measurements of GFR through 
measured urine creatinine clearance or iothalamate studies, thus limiting its efficacy on 
true graft function. Case 1 had the biopsy performed before conversion to belatacept, 
while Case 2 had the biopsy performed while TAC was minimized but not eliminated. In 
Case 2, although the timing of the biopsy was not preconversion, the fact that elimination 
of TAC significantly improved the graft function back to normal levels supports the 
diagnosis of CNI‐induced nephrotoxicity. It is also possible that there are different cellular 
and immunological mechanisms in play preventing the pancreas from rejection and this 
effect may not be solely due to the belatacept maintenance therapy as both patients had 
received rituximab. 
Our reported short‐term experience with belatacept therapy in these two patients is 
encouraging as we did not observe development of postswitch DSA, anti‐insulin 
autoantibodies, infections, posttransplant lymphoproliferative disorder or any clinical 
evidence of pancreatic allograft dysfunction. In our two cases with unusually rapid 
deterioration of renal function, stopping the CNI and starting belatacept led to 
improvement of renal function without evidence of kidney or pancreas rejection. Pancreas 
rejections can be devastating with potential for necrosis, abscess or enteric perforations 
and gastro‐intestinal hemorrhage. Currently there are ongoing studies using belatacept 
 
 
in SPK (www.clinicaltrials.gov; NCT01790594; CTOT 15). Hence, before we can 
recommend using belatacept to prevent CKD progression in the pancreas transplant 
population, the authors recommend waiting for such studies or an SPK conversion study 
be undertaken in a systematic fashion. 
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